Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:AKBA NASDAQ:ANL NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.72-2.1%$0.89$0.63▼$1.45$18.26M0.61125,999 shs18,221 shsAKBAAkebia Therapeutics$0.94-3.6%$1.25$0.88▼$4.08$250.90M0.265.23 million shs1.85 million shsANLAdlai Nortye$9.95-9.5%$12.05$0.88▼$17.25$398M0.93138,161 shs147,125 shsSIGASiga Technologies$4.30-2.9%$4.64$4.09▼$9.62$308.41M0.91513,622 shs550,809 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-2.87%-4.91%-20.30%-31.92%+10.27%AKBAAkebia Therapeutics-3.58%-8.30%-36.80%-26.35%-74.30%ANLAdlai Nortye-9.55%-16.67%-30.27%+11.67%+485.29%SIGASiga Technologies-2.93%-8.12%-8.51%-25.86%-30.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.72-2.1%$0.89$0.63▼$1.45$18.26M0.61125,999 shs18,221 shsAKBAAkebia Therapeutics$0.94-3.6%$1.25$0.88▼$4.08$250.90M0.265.23 million shs1.85 million shsANLAdlai Nortye$9.95-9.5%$12.05$0.88▼$17.25$398M0.93138,161 shs147,125 shsSIGASiga Technologies$4.30-2.9%$4.64$4.09▼$9.62$308.41M0.91513,622 shs550,809 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-2.87%-4.91%-20.30%-31.92%+10.27%AKBAAkebia Therapeutics-3.58%-8.30%-36.80%-26.35%-74.30%ANLAdlai Nortye-9.55%-16.67%-30.27%+11.67%+485.29%SIGASiga Technologies-2.93%-8.12%-8.51%-25.86%-30.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AAKBAAkebia Therapeutics 2.20Hold$4.67398.95% UpsideANLAdlai Nortye 2.60Moderate Buy$24.25143.72% UpsideSIGASiga Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ANL, AKBA, SIGA, and AEON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/28/2026ANLAdlai Nortye OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.005/27/2026AEONAEON Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/11/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026ANLAdlai Nortye HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$16.00 ➝ $20.004/10/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AAKBAAkebia Therapeutics$236.20M1.06N/AN/A$0.12 per share7.79ANLAdlai Nortye$5M79.60N/AN/A($0.21) per share-47.38SIGASiga Technologies$94.57M3.26$0.33 per share12.92$2.78 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$5.004.01N/AN/AN/AN/A-994.63%8/11/2026 (Estimated)AKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)ANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)SIGASiga Technologies$23.28M$0.2715.93N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)Latest ANL, AKBA, SIGA, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 million3/10/2026Q4 2025SIGASiga TechnologiesN/A-$0.08N/A-$0.08N/A$3.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest ANL, AKBA, SIGA, and AEON DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2026SIGASiga Technologiesspecial$0.604/7/20264/7/20264/23/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22AKBAAkebia Therapeutics1.331.401.33ANLAdlai NortyeN/A0.650.65SIGASiga TechnologiesN/A3.252.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%AKBAAkebia Therapeutics33.92%ANLAdlai Nortye35.21%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma9.40%AKBAAkebia Therapeutics4.30%ANLAdlai NortyeN/ASIGASiga Technologies2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma525.30 million74.37 millionNot OptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableSIGASiga Technologies4071.72 million69.77 millionOptionableANL, AKBA, SIGA, and AEON HeadlinesRecent News About These CompaniesDiscovering SIGA Technologies And 2 Other Compelling Penny StocksMay 22, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's ChangedMay 15, 2026 | finance.yahoo.comSome Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft EarningsMay 14, 2026 | finance.yahoo.comSiga Technologies Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comSIGA (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | fool.comSIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 monthsMay 8, 2026 | msn.comSIGA Technologies, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comSIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comSIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business UpdateMay 7, 2026 | globenewswire.comSIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%March 28, 2026 | aaii.comASIGA mpox therapy no longer recommended in EUMarch 27, 2026 | msn.comSiga Technologies Declares Special Dividend of 60 CentsMarch 26, 2026 | marketwatch.comSIGA Declares Special Cash Dividend of $0.60 Per ShareMarch 26, 2026 | globenewswire.comSiga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 IndexMarch 19, 2026 | kalkinemedia.comKMpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.March 17, 2026 | barrons.comA Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract ProgressMarch 15, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract WinsMarch 15, 2026 | finance.yahoo.comSIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy RevenueMarch 14, 2026 | finance.yahoo.comSIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...March 11, 2026 | finance.yahoo.comSIGA outlines continued TPOXX global expansion and expects EMA smallpox decision in March 2026March 10, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANL, AKBA, SIGA, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.72 -0.02 (-2.12%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$0.72 +0.00 (+0.32%) As of 06/5/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Akebia Therapeutics NASDAQ:AKBA$0.94 -0.04 (-3.61%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.98 +0.04 (+4.67%) As of 06/5/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Adlai Nortye NASDAQ:ANL$9.95 -1.05 (-9.55%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$9.86 -0.09 (-0.95%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Siga Technologies NASDAQ:SIGA$4.30 -0.13 (-2.93%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.32 +0.03 (+0.58%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
